TheraRadar
Data updated: Jun 28, 2026

LO JUNEL FE (ethinyl estradiol)

Approved 2026-06-22
1
Indication
--
Phase 3 Trials
0
Years on Market

Details

Status
Prescription
First Approved
2026-06-22
Routes
ORAL
Dosage Forms
TABLET

Companies

LO JUNEL FE Approval History

Original
New Indication
New Form
Label Update
1 FDA actions from 2026 to 2026
Jun 2026 ORIGINAL
Update

What LO JUNEL FE Treats

1 FDA approvals

Originally approved for its first indication in 2026 .

  • Other (1)

Teva's other novel FDA approvals

Other CDER-designated drugs from the same sponsor (2016–2025).

📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT07340190 CDAK539A12102 2025-521000-22-00 Ph 1 recruiting A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
NCT06039826 18533 J1I-MC-GZBV Ph 1 completed A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LO JUNEL FE FDA Label Details

Track LO JUNEL FE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.